advertisement
Abstract #6832 Published in IGR 4-1
Travoprost, a new prostaglandin analogue for glaucoma treatment
Hommer A; Huber Spitzy V; Kaminski SSpektrum der Augenheilkunde 2002; 16: 11-16
Travoprost, given qd in the evening, as an esterified PGF2 analogue, is a highly selective potent prostaglandin-F-receptor agonist. It is superior to timolol 0.5% b.i d. (8.0-8.9 mmHg versus 6.3-7.9 mmHg) and at least as effective in lowering the intraocular pressure compared to latanoprost (0.005%) in patients with open-angle glaucoma or ocular hypertension. It is given once daily in the evening. The most frequent reported treatment related adverse event is ocular hyperemia of a predominantly mild to moderate grade. Eyelash changes and iris hyperpigmentation are observed approximately at the same rate as with latanoprost.LA: German
Dr. A. Hommer, Sanatorium Hera, Augenheilkunde, Loblichgasse 14, 1090 Vienna, Austria
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
